ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.
"Our TAP technology has an unmatched level of reported clinical data, and this body of data will expand meaningfully at ASCO this year," said Daniel Junius, President and CEO. "On June 4th, the first clinical data for SAR3419 dosed weekly will be reported. We believe these data will provide insight into Sanofi's interest in advancing SAR3419 into Phase II testing later this year. Then, on June 5th, there will be an oral presentation featuring interim findings with our IMGN901 compound used in a combination regimen to treat multiple myeloma. The tolerability profile of IMGN901, and other TAP compounds, supports assessment as part of combination regimens, which we believe is an important development path for IMGN901."
Saturday, June 4 - SAR3419 poster presentation with oral discussion
"Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)." (abstract #8017):
- Poster presentation: 8:00 am-12:00 noon CT, room E450b, Poster 3
- Oral discussion session: 12:00 noon-1:00 pm CT, room E354a
Sunday, June 5 - IMGN901 oral presentation
"Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM)."(abstract #8013):
- Oral presentation: 11:30-11:45 am CT, room E354a
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR